Financings in Brief: T Cell Sciences
This article was originally published in The Gray Sheet
Executive Summary
T Cell Sciences: Raises $6.4 mil. in private placement of 2.55 mil. shares of common stock. "Several institutional investors and private investors" participated in the placement, the firm says. T Cell's diagnostics subsidiary received 510(k) clearance from FDA earlier this year for its TRAx CD4 immunoassay test kit ("The Gray Sheet" May 22, p. 18). However, most of the proceeds from the offering will be put toward advancing the company's complement inhibitor program, T Cell says...